| 15.13 -0.99 (-6.14%) | 11-11 15:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.35 | 1-year : | 20.8 |
| Resists | First : | 16.56 | Second : | 17.81 |
| Pivot price | 16.43  |
|||
| Supports | First : | 14.55 | Second : | 12.1 |
| MAs | MA(5) : | 15.71 |
MA(20) : | 16.33 |
| MA(100) : | 14.37  |
MA(250) : | 11.65 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 21.3 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 17.81 | Low : | 7.84 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BWAY ] has closed below the lower bollinger band by 4.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BWAY ] is to continue within current trading range. Bollinger Bands are 8.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.53 - 16.61 | 16.61 - 16.68 |
| Low: | 15.75 - 15.84 | 15.84 - 15.93 |
| Close: | 15.97 - 16.12 | 16.12 - 16.26 |
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Tue, 11 Nov 2025
BWAY Raises 2025 Financial Outlook with Improved Revenue and Inc - GuruFocus
Mon, 10 Nov 2025
What To Expect From BrainsWay Ltd (BWAY) Q3 2025 Earnings - Yahoo Finance
Fri, 07 Nov 2025
Brainsway Ltd expected to post earnings of 6 cents a share - Earnings Preview - TradingView
Wed, 05 Nov 2025
Brainsway (BWAY) Projected to Post Earnings on Tuesday - MarketBeat
Tue, 28 Oct 2025
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Tue, 28 Oct 2025
BrainsWay (NASDAQ: BWAY) sets third quarter results Nov. 11; call 8:30 AM ET - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 19 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 33.8 (%) |
| Shares Short | 150 (K) |
| Shares Short P.Month | 206 (K) |
| EPS | 0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.79 |
| Profit Margin | 11.6 % |
| Operating Margin | 4.5 % |
| Return on Assets (ttm) | 1.3 % |
| Return on Equity (ttm) | 9.6 % |
| Qtrly Rev. Growth | 26.2 % |
| Gross Profit (p.s.) | 1.8 |
| Sales Per Share | 2.42 |
| EBITDA (p.s.) | 0.17 |
| Qtrly Earnings Growth | 124.3 % |
| Operating Cash Flow | 23 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | 53.92 |
| PEG Ratio | 0 |
| Price to Book value | 8.38 |
| Price to Sales | 6.22 |
| Price to Cash Flow | 12.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|